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Abstract
Background: Fatty acid-induced insulin resistance and impaired glucose uptake activity in muscle cells are
fundamental events in the development of type 2 diabetes and hyperglycemia. There is an increasing demand for
compounds including drugs and functional foods that can prevent myocellular insulin resistance.
Methods: In this study, we established a high-throughput assay to screen for compounds that can improve
myocellular insulin resistance, which was based on a previously reported non-radioisotope 2-deoxyglucose (2DG)
uptake assay. Insulin-resistant muscle cells were prepared by treating rat L6 skeletal muscle cells with 750 μM
palmitic acid for 14 h. Using the established assay, the impacts of several fatty acids on myocellular insulin
resistance were determined.
Results: In normal L6 cells, treatment with saturated palmitic or stearic acid alone decreased 2DG uptake, whereas
unsaturated fatty acids did not. Moreover, co-treatment with oleic acid canceled the palmitic acid-induced
decrease in 2DG uptake activity. Using the developed assay with palmitic acid-induced insulin-resistant L6 cells, we
determined the effects of other unsaturated fatty acids. We found that arachidonic, eicosapentaenoic and
docosahexaenoic acids improved palmitic acid-decreased 2DG uptake at lower concentrations than the other
unsaturated fatty acids, including oleic acid, as 10 μM arachidonic acid showed similar effects to 750 μM oleic acid.
Conclusions: We have found that polyunsaturated fatty acids, in particular arachidonic and eicosapentaenoic acids
prevent palmitic acid-induced myocellular insulin resistance.
Keywords: Insulin resistance, Glucose uptake, L6 skeletal muscle cells, Palmitic acid, Arachidonic acid, Eicosapentae-
noic acid
Background
Insulin resistance is an impaired response to insulin in
specific organs or cells such as liver, fat and muscle, and
is strongly associated with the development of obesity
and type 2 diabetes [1]. Elevated plasma free fatty acid
levels is an important factor, because it causes insulin
resistance in skeletal muscle, the major site for blood
glucose disposal [2]. Thus, many studies have been
reported on the relationship between fatty acids and
insulin resistance, and revealed that saturated fatty
acids, particularly palmitic acid, induce insulin resistance
in myotubes [3], whereas unsaturated fatty acids do not
[4,5]. In skeletal muscle, insulin resistance is mediated
by the intramyocellular accumulation of the metabolites
of saturated palmitic acid, namely diacylglycerol (DAG)
and ceramide. DAG downregulates insulin-sensitive glu-
cose transporter type 4 (GLUT4) and insulin receptor
(IR) by activating the inflammatory transcription factor
nuclear factor (NF)-B [6]. Ceramide inhibits protein
kinase B (PKB/Akt) activity which plays an important
role in insulin signaling [7,8]. The levels of these meta-
bolites progressively increase as insulin resistance wor-
sens [9-11], and further decrease glucose uptake activity
in myotubes.
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any medium, provided the original work is properly cited.There is an increasing demand for drugs and func-
tional foods that are capable of regulating blood glucose
levels. Several unsaturated fatty acids, including palmito-
leic and oleic acids, were reported to ameliorate palmitic
acid-induced insulin resistance in myotubes [4,12,13].
Coll et al. (2008) reported that oleic acid inhibited intra-
myocellular DAG accumulation by enhancing b-oxida-
tion of palmitoyl CoA and upregulating diacylglycerol
acyltransferase 2, an enzyme that synthesizes triacylgly-
cerol from DAG, which ultimately inhibited palmitic
acid-induced downregulation of IR [12]. Chen et al.
have reported that berberine, an isoquinoline alkaloid,
improves palmitic acid-induced insulin resistance in L6
myotubes by inhibiting peroxisome proliferator-activated
receptor (PPAR)-g [14]. Other than these compounds,
little is known about inhibitors of palmitic acid-induced
insulin resistance in muscle cells.
In these earlier studies, insulin resistance was evalu-
ated based on downregulation of IR and GLUT4 expres-
sion or decreased radioisotope-labeled glucose uptake
[15-22]. We recently reported an enzymatic 2DG uptake
assay, which had greater processing capacity compared
with these conventional tools [23,24]. This enzymatic
assay enables us to measure 2DG uptake into myotubes
cultured in a 96-well microplate by measuring the fluor-
escence of resorufin, which is derived from resazurin,
and is appropriate to screen for compounds capable of
regulating 2DG uptake, including polyphenols [25,26].
In this study, we report our development of a high-
throughput procedure to screen for compounds that can
prevent palmitic acid-induced myocellular insulin resis-
tance using this enzymatic 2DG uptake assay, and
assessment of the anti-insulin-resistant effects of unsatu-
rated fatty acids.
Results
Determination of optimum treatment time and
concentration of palmitic acid
To induce insulin resistance in muscle cells, we treated
differentiated L6 skeletal muscle cells with palmitic acid
according to a method reported by Chaves et al. [7].
Treatment-time and concentration of palmitic acid were
defined by evaluating the decreases in IR expression,
cellviability and 2DG uptake activity. Treating cells with
750 μM palmitic acid for 24 h significantly decreased IR
expression (Figure 1A). After we confirmed that palmitic
acid did not show significant cytotoxicity by 900 μM,
the treatment concentration was fixed at 750 μM
according to the previous reports [4,6] (Figure 1B). This
concentration of palmitic acid also decreased IR expres-
sion after 14 and 16 h of treatment (Figure 1B), and
decreased basal and insulin-induced 2DG uptake activity
in a time-dependent manner (Figure 1C). The decrease
in 2DG uptake activity was well correlated with the
decrease in IR expression. Based on these results, we
prepared insulin-resistant cells in the following experi-
ments by treating differentiated L6 cells with 750 μM
palmitic acid for 14 h.
Effect of fatty acids on myocellular glucose uptake
activity
We used the enzymatic 2DG uptake assay to evaluate
the effects of several saturated and unsaturated fatty
acids commonly contained in food on the development
of insulin resistance. Palmtic acid (16:0) significantly
decreased glucose uptake activity to 19% and 33% in the
absence and presence of insulin, respectively (Figure
2A). Stearic acid (18:0) also significantly decreased 2DG
uptake, although its effect was weaker than that of pal-
mitic acid.
On the other hand, the unsaturated forms of these
fatty acids, such as palmitoleic (16:1), oleic (18:1), lino-
leic (18:2) and a-linolenic acid (18:3), only affected 2DG
uptake activity in the presence of insulin. Other polyun-
saturated fatty acids, including arachidonic (20:4), doco-
sahexaenoic (22:6) and eicosapentaenoic acids (20:5),
were tested at a lower concentration (100 μM) because
arachidonic and docosahexaenoic acids were cytotoxic
at 750 μM (Figure 2B). These three polyunsaturated
fatty acids did not affect 2DG uptake activity (Figure
2A). Palmitic acid showed the strongest effect in terms
of decreasing 2DG uptake activity. These results confirm
that palmitic acid is an appropriate inducer of myocellu-
lar insulin resistance.
Effects of unsaturated fatty acids on palmitic acid-
induced insulin resistance
To confirm the effects of oleic acid on palmitic acid-
induced insulin resistance, L6 myotubes were simulta-
neously treated with palmitic acid and oleic acid. In this
assay, oleic acid canceled palmitic acid-induced
decreases in IR and GLUT4 expression (Figure 3A), as
expected. Furthermore, oleic acid dose-dependently
inhibited the palmitic acid-induced decrease in 2DG
uptake activity (Figure 3B). These results indicate that
the enzymatic 2DG uptake assay using palmitic acid-
treated cells is useful to screen for compounds that reg-
ulate insulin resistance in skeletal muscle cells.
Since 750 μM oleic acid showed the strongest effect
on the recovery of 2DG uptake in palmitic acid-treated
L6 cells, we evaluated the effects of other fatty acids at
750 μM on palmitic acid-induced insulin resistance.
Compared with palmitic acid treatment alone, cotreat-
ment with stearic acid evoked a further decrease in 2DG
uptake activity in L6 myotubes (Figure 4A). All of the
unsaturated fatty acids including oleic acid could cancel
decrease in 2DG uptake activity induced by palmitic
acid. Interestingly, polyunsaturated fatty acids were
Sawada et al. Lipids in Health and Disease 2012, 11:36
http://www.lipidworld.com/content/11/1/36
Page 2 of 9Palmitic acid (ȝM):
0
3
7
5
7
5
0
1
1
2
5
1
5
0
0
(A)
0 8 10 12 14 16 Treatment time with 
ȝ0SDOPLWLFDFLG (h):
(B)
E-actin ĺ
IRĺ
E-actin ĺ
IRĺ
2
D
G
u
p
t
a
k
e
 
(
n
g
/
w
e
l
l
)
- 8 10 12 14 16
a
a a
b
c
d c d
e e
e
e
e e
(D) 
24 h-treatment
7UHDWPHQWWLPHZLWKȝ0palmitic acid (h)
0
100
200
300
400
+ insulin - insulin
(C)
C
e
l
l
 
v
i
a
b
i
l
i
t
y
(
%
 
c
o
n
t
r
o
l
)
0
20
40
60
80
100
120
0 400 800 1200 1600
Treatment concentration with SDOPLWLFDFLGȝ0
24 h-treatment
* ** **
Figure 1 Palmitic acid downregulates IR expression and 2DG uptake activity. Differentiated L6 cells were incubated with the indicated
concentrations of palmitic acid for the indicated times. Dose-dependent effect of palmitic acid on (A) IR expression detected by western
blotting, and (B) cell viability determined by crystal violet staining. (C) Time-dependent effect of palmitic acid on IR expression determined by
western blotting. (D) Time-dependent effects of palmitic acid on 2DG uptake activity in the absence or presence of 100 nM insulin. * and **
indicate significant difference vs control at p < 0.05 and p < 0.01, respectively, for panel (B). Different letters indicate significant changes (p <
0.05) for panel (D).
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Page 3 of 9much more effective. For example, 100 μM docosahex-
aenoic acid and eicosapentaenoic acid elicited similar
effects to 750 μM oleic acid (Figure 4A). Moreover, ara-
chidonic acid was more effective than the other polyun-
saturated fatty acids at 10 and 50 μM (Figure 4B), with
significant effects at 10 μM. It was confirmed that eico-
sapentaenoic acid was also effective at the lower concen-
trations. As shown in Figure 4C, significant recovery
effect of arachidonic acid on 2DG uptake was observed
at 10 μM and reached maximum levels at 50 μM and 75
μM in the presence and absence of insulin, respectively.
We further investigated whether treated fatty acids
would incorporated into the cells by measuring fatty
acid contents in the cells treated with 750 μM palmitic
acid or 50 μM arachidonic acid (Figure 5). It was con-
firmed that intracellular contents of the treated fatty
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Figure 2 Fatty acid-induced decreases in 2DG uptake activity and viability of L6 cells. (A) Differentiated L6 cells were incubated with the
indicated fatty acid (750 μM palmitic, stearic, palmitoleic, oleic, linoleic or a-linolenic acids; or 100 μM arachidonic, docosahexaenoic or
eicosapentaenoic acid) for 14 h. 2DG uptake activity was measured in the absence or presence of 100 nM insulin. (B) Cell viability was
determined by crystal violet staining after treatment with the indicated concentrations of arachidonic, docosahexaenoic and eicosapentaenoic
acids for 24 h. Different letters indicate significant changes (p < 0.05) for panel (A). * indicates significant difference vs control at p < 0.05 for
panel (B)
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Figure 3 Effects of oleic acid on palmitic acid-induced decreases in IR and GLUT4 expression and 2DG uptake activity. Differentiated L6
myotubes were treated with 750 μM palmitic acid without or with the indicated concentrations of oleic acid for 14 h. (A) IR and GLUT4
expression determined by western blotting. (B) Dose-dependent effects of oleic acid on 2DG uptake activity in the presence of 750 μM palmitic
acid in the absence or presence of 100 nM insulin. Different letters indicate significant changes (p < 0.05).
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Figure 4 Effects of arachidonic acid and other fatty acids on palmitic acid-induced decreases in 2DG uptake activity. Differentiated L6
myotubes were treated with 750 μM palmitic acid without or with the indicated fatty acids [(A) 750 μM stearic, palmitoleic, oleic, linoleic or a-
linolenic acid; or 100 μM docosahexaenoic and eicosapentaenoic acid; (B) 10 and 50 μM arachidonic, eicosapentaenoic, or docosahexaenoic
acid)] for 14 h. (C) Differentiated L6 myotubes were treated with 10-100 μM arachidonic acid as in (A). After treatment with the fatty acids, 2DG
uptake activity was measured in the absence or presence of 100 nM insulin. Different letters indicate significant changes (p < 0.05).
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Page 5 of 9acids were significantly higher than those of non-treated
cells; i.e., content of palmitic acid increased 3-fold while
that of arachdonic acid 2-fold. Co-treatment with palmi-
tic and arachidonic acids also increased both fatty acids
in the cells.
Discussion
The in vitro evaluation of compounds that can affect
insulin resistance in myotubes has long been performed
by measuring the changes in uptake of radiolabeled glu-
cose analogs and/or in the expression and phosphoryla-
tion of components of the insulin signaling pathways
[15-22]. However, these conventional approaches are
unsuitable for high-throughput screening, because radi-
olabeled analogs are costly and require specialized
equipments, and both approaches have low processing
capacity. Our research group previously reported a high-
throughput enzymatic 2DG uptake assay system [23,24].
In the present study, we developed a high-throughput
assay based on this previously reported assay system to
screen for compounds that can ameliorate insulin resis-
tance in L6 myotubes. Using this system, we found that
arachidonic, eicosapentaenoic, and docosahexaenoic
acids were more effective than oleic acid [12,13] in
terms of ameliorating insulin resistance.
In this study, we first confirmed that saturated palmi-
tic and stearic acids decreased glucose uptake by L6
myotubes, whereas their unsaturated forms (i.e., oleic,
palmitoleic, linoleic and a-linolenic acids) did not.
These results are consistent with previous reports [4,5].
Indeed, it was reported that myocellular insulin resis-
tance is mediated by the accumulation of the saturated
fatty acid metabolites DAG and ceramide. DAG acti-
vates novel PKCs that downregulate GLUT4 and IR
expression by activating NF-B [6]. Ceramide inhibits
PKB/Akt activity, which plays an important role in insu-
lin signaling [7,8]. Palmitic acid is a stronger inducer of
the accumulation of these metabolites and the transcrip-
tional activity of NF-B compared as stearic acid [3],
which is correlated with the greater decrease in glucose
uptake activity in palmitic acid-treated cells. These facts
and the obtained results indicate that our assay with
palmitic acid-induced insulin resistant L6 myotubes is
suitable to screen for compounds that can induce or
prevent insulin resistance.
Using palmitic acid as an inducer of insulin resistance,
we tested the anti-insulin resistant effects of several fatty
acids. All of the unsaturated fatty acids tested in this
study, namely palmitoleic, oleic, linoleic, linolenic, ara-
chidonic, docosahexaenoic and eicosapentaenoic acids,
ameliorated palmitic acid-induced decrease in 2DG
uptake (Figure 4). Unsaturated fatty acids, in particular
polyunsaturated fatty acids, are known to be oxidized
easily. Therefore, to investigate whether the recovery of
2DG uptake was dependent on the exogenously added
fatty acids per se or their oxidized derivatives, we
* * *
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Figure 5 Effect of exogenously added palmitic and oleic acids on cellular fatty acid contents. Differentiated L6 myotubes were treated
with 750 μM palmitic acid and/or 50 μM arachidonic acid for 14 h. Intracellular fatty acid contents were measured by using a gas
chromatography. * indicates significant difference vs control at p < 0.05.
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hydroxytoluene (BHT). In the presence of 0.2 mM BHT
in the medium, palmitic acid-induced decrease and its
amelioration by arachidonic acid were confirmed(data
not shown). However, 2DG uptake was decreased by
treatment with BHT alone, indicating that BHT itself
affected cellular functions under our experimental con-
ditions. Meanwhile, Figure 5 shows that treated palmitic
and arachidonic acid were increased in the cells. These
results suggest that the exogenously added arachidonic
acid and other unsaturated fatty acids are incorporated
into the cells, and contribute to their anti-insulin resis-
tant effects.
Of the tested unsaturated fatty acids, oleic acid has
been a focus of many researches. The effects of oleic
acid were reported to be dependent on its ligand activity
for PPARa which plays essential roles in regulation of
lipid metabolism [27]. PPARa activation improves intra-
myocellular DAG accumulation by accelerating b-oxida-
tion and upregulating DAG acyltransferase 2, an enzyme
that synthesizes triacylglycerol from DAG [12]. The
effects of other fatty acids would depend, at least in
part, on PPARa because of its high affinity for unsatu-
rated fatty acids [27,28]. Our results indicate that the
effects of arachidonic, eicosapentaenoic and docosahex-
aenoic acids at much lower concentrations compared
with oleic acid (Figure 4A and 4C). This result strongly
suggests that bioactive metabolites of these polyunsatu-
rated fatty acids are involved in underlying mechanism.
Indeed, prostaglandin E2, a metabolite of n-6 polyunsa-
turated fatty acids, ameliorated the palmitic acid-
induced inflammation, and recovered PKB/Akt phos-
phorylation level and glucose uptake in muscle cells
[29]. Therefore, the results obtained for polyunsaturated
fatty acids in our assay are mainly due to their PPARa
ligand activity or anti-inflammatory activity. However,
the mechanisms by which arachidonic, eicosapentaenoic
and docosahexaenoic acids ameliorated insulin resis-
tance, which seem to be independent of the mechanisms
exploited by the other unsaturated fatty acids tested,
remain unclear. Further studies are needed to clarify the
underlying mechanisms.
Conclusions
We developed a high-throughput assay to screen for
compounds that can improve palmitic acid-induced
insulin resistance by modifying our previously estab-
lished enzymatic 2DG uptake assay [23,24]. Using the
developed assay, we determined the ameliorative effects
of several polyunsaturated fatty acids on insulin resis-
tance. Notably, arachidonic, eicosapentaenoic and doco-
sahexaenoic acids showed were more potent than the
other unsaturated fatty acids tested in this study.
Methods
Materials
Minimum essential medium (MEM), 2-deoxyglucose
(2DG), glucose-6-phosphate dehydrogenase (G6PDH),
resazurin and stearic acid (Sigma, St. Louis, MO); dia-
phorase and b-nicotinamide adenine dinucleotide phos-
phate (b-NADP+; Oriental Yeast, Tokyo, Japan);
arachidonic acid, docosahexaenoic acid and eicosapen-
taenoic acid (Cayman Chemical,Ann Arbor, MI); fetal
bovine serum (FBS; Biological Industries, Kibbutz Beit
Haemek, Israel); palmitoleic acid and bovine serum
albumin (BSA; Nakarai Tesque, Kyoto, Japan) and
Lumi-Light Plus Western Blotting Substrate
® (Roche
Diagnostics, Mannheim, Germany) were purchased from
commercial sources. Anti-GLUT4, anti-IR, anti-goat IgG
and anti-rabbit IgG antibodies were purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). All other
reagents were purchased from WAKO Pure Chemicals
(Osaka, Japan), unless otherwise specified.
Cell culture
Rat skeletal muscle L6 cells (passages 27-38) were main-
tained in MEM supplemented with 10% FBS, 100 U/mL
penicillin, and 100 μg / m Ls t r e p t o m y c i na t3 7 ° Ci na
humidified atmosphere with 5% CO2. To induce differ-
entiation into myotubes, L6 cells were seeded on 96-
well plates (4 × 103 cells/0.2 mL), 60-mm dishes (1.2 ×
105 cells/4 mL), or 35-mm dishes (4 × 104 cells/1 mL)
in culture medium. After 2 days, the medium was
replaced with MEM containing 2% FBS and antibiotics,
which was changed every other day. L6 cells were used
for experiments after 5 days of differentiation. Fatty
acid-containing media were prepared by conjugating
fatty acids to BSA, as previously described [7], but with
some modifications. Briefly, palmitate was dissolved in
ethanol and diluted in MEM containing 2% (w/v)B S A .
The cells were incubated for 14 h in MEM containing
2% FBS and 2% BSA in either the presence or absence
of fatty acids. The treated cells were used for western
blotting analysis and 2DG uptake assays.
Western blotting
After treatment with fatty acids, the cells plated on 60-
mm dishes were washed twice with Krebs-Ringer
HEPES buffer (KRH; 50 mM HEPES, pH 7.4, 137 mM
sodium chloride, 4.8 mM potassium chloride, 1.85 mM
calcium chloride, 1.3 mM magnesium sulfate) and
homogenized with RIPA buffer [50 mM Tris, pH8.0,
150 mM sodium chloride, 0.5% (w/v) sodium deoxycho-
late, 1% (w/v) sodium dodecyl sulfate, 1% (v/v)N o n i d e t
P-40] containing protease and phosphatase inhibitors.
The cell lysate was incubated on ice for 1 h with occa-
sional mixing. After centrifugation at 16,000 × g for 20
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Page 7 of 9min at 4°C, the supernatant was collected and used as
whole protein. Aliquots of whole protein were separated
on 10% polyacrylamide gels and transferred to polyviny-
lidene difluoride membranes (Biotrace, Pall Corporation,
Port Washington, NY). After blocking with Blocking
one
® (Nakarai Tesque), the membranes were treated
with appropriate specific primary antibodies for 1 h at
room temperature, followed by the corresponding horse-
radish peroxidase-conjugated secondary antibody for 1 h
at room temperature. Specific immune complexes were
detected using ECL plus kits (GE Healthcare Bio-
Sciences Corporation, Tokyo, Japan).
Glucose uptake assay
Glucose uptake in L6 myotubes was measured using an
enzymatic 2DG uptake assay as previously described
[23,24], with some modifications. L6 myotubes on a 96-
well plate were serum-starved in 0.2% BSA/MEM for 18
h and were treated with DMSO and insulin (final con-
centration, 0.1 μM) in the same media. The cells were
washed twice with KRH buffer containing 0.1% (w/v)
BSA and incubated with 1 mM 2DG in 0.1% (w/v) BSA/
KRH buffer for 20 min at 37°C in 5% CO2. They were
then washed twice with 0.1% (w/v) BSA/KRH buffer,
lysed with 0.1 N sodium hydroxide, warmed at 60°C for
10 min, and dried at 85°C for 50 min. The dried cell
lysate was solubilized with 0.1 N hydrochloric acid and
200 mM triethanolamine (TEA) (pH 8.1), and gently
stirred using a microplate shaker. The lysate was mixed
with an assay cocktail [50 mM TEA, pH 8.1, 50 mM
KCl, 0.02% (w/v)B S A ,0 . 1m Mb-NADP+, 2 units dia-
phorase, 150 units G6PDH, 2 μMr e s a z u r i n ]o na n o t h e r
96-well plate and incubated at 37°C for 50 min. The
fluorescence of resorufin was measured at 570 nm with
excitation at 530 nm using a Wallac 1420 ARVOsx (Per-
k i n - E l m e r ,B o s t o n ,M A ) .T h e2 D Gc o n c e n t r a t i o ni n
each well was calculated based on a standard curve gen-
erated with a 2DG-6-phosphate solution.
Cytotoxicity
The cytotoxicity of fatty acids was determined by crystal
violet staining [25]. Differentiated L6 cells on 96-well
microplate were treated with ethanol or fatty acids (300,
450, 600, 750, 900, 1050, 1200, 1350 and 1500 μMf o r
Figure 1B; and 10, 25, 50, 100, 250 and 750 μM for Fig-
ure 2B) in MEM containing 2% BSA for 24 h, and then
stained with 2% ethanol containing 0.2% (w/v) crystal
violet for 10 min. The wells were washed three times
with tap water, and the stained cells were extracted with
50% ethanol containing 0.5% (w/v) sodium dodecyl sul-
fate. The absorbance at 570 nm with a reference wave-
length of 630 nm was measured using the Wallac 1420
ARVOsx.
Measurement of fatty acid contents
L6 myotubes on a 35-mm culture dish were incubated
for 14 h in MEM containing 2% FBS and 2% BSA in
either the presence or absence of palmitic and arachido-
nic acids. The treated cells were washed with 2% BSA/
KRH for 3 times, and with phosphatydyl buffer serine
twice, and collected with phosphate buffered saline (137
mM sodium chloride, 8.10 mM sodium phosphate diba-
sic, 2.68 mM potassium chloride, 1.47 mM potassium
phosphate monobasic). Intracellular fatty acid contents
were measured by using a gas chromatography accord-
ing to previous report with slight modification [30].
Briefly, lipids were extracted from the cells by chloro-
form:methanol (2:1, v/v). hydolized and methylated with
potassium hydroxide in methanol, and subjected to a
GC2010 gas chromatograph (Shimadzu Co., Kyoto,
Japan) equipped with DB23 column (Agilent J&W, Fol-
som, CA).
Statistical analysis
Data are shown as means ± SD of results from three
independent experiments. Statistical analyses were per-
formed using the Tukey-Kramer test, except for the
cytotoxicity tests (Dunnet test, for Figures 1B and 2B).
Values of p < 0.05 were considered significant.
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